Aequus Pharmaceuticals Inc (AQS) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.003x

Based on the latest financial reports, Aequus Pharmaceuticals Inc (AQS) has a cash flow conversion efficiency ratio of 0.003x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-21.22K ≈ $-15.35K USD) by net assets (CA$-6.89 Million ≈ $-4.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Aequus Pharmaceuticals Inc (AQS) market capitalisation for the company's overall valuation and market capitalisation.

Aequus Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Aequus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Aequus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Aequus Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore Aequus Pharmaceuticals Inc earnings quality ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
STMicroelectronics NV LSE:0INB	0.221x
Craven House Capital PLC LSE:CRV	0.000x
Watkin Jones PLC LSE:WJG	-0.050x
Faron Pharmaceuticals Oy LSE:FARN	0.000x
Angling Direct PLC LSE:ANG	0.059x
Zapp Electric Vehicles Group Limited Ordinary Shares NASDAQ:ZAPP	0.000x
PURANIUM ENERGY LTD. F:2DK	0.113x
Baosheng Media Group Holdings Ltd NASDAQ:BAOS	-0.522x

Annual Cash Flow Conversion Efficiency for Aequus Pharmaceuticals Inc (2013–2024)

The table below shows the annual cash flow conversion efficiency of Aequus Pharmaceuticals Inc from 2013 to 2024. View Aequus Pharmaceuticals Inc (AQS) stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CA$-6.45 Million ≈ $-4.67 Million	CA$-1.66 Million ≈ $-1.20 Million	0.257x	-51.98%
2023-12-31	CA$-4.29 Million ≈ $-3.11 Million	CA$-2.29 Million ≈ $-1.66 Million	0.534x	-62.24%
2022-12-31	CA$-1.38 Million ≈ $-998.30K	CA$-1.95 Million ≈ $-1.41 Million	1.415x	+315.94%
2021-12-31	CA$1.79 Million ≈ $1.29 Million	CA$-1.17 Million ≈ $-847.96K	-0.655x	+53.28%
2020-12-31	CA$573.95K ≈ $415.19K	CA$-804.91K ≈ $-582.26K	-1.402x	-175.50%
2019-12-31	CA$-877.09K ≈ $-634.48K	CA$-1.63 Million ≈ $-1.18 Million	1.857x	+221.37%
2018-12-31	CA$1.68 Million ≈ $1.22 Million	CA$-2.57 Million ≈ $-1.86 Million	-1.530x	+7.45%
2017-12-31	CA$2.31 Million ≈ $1.67 Million	CA$-3.81 Million ≈ $-2.76 Million	-1.654x	+53.13%
2016-12-31	CA$1.27 Million ≈ $915.58K	CA$-4.47 Million ≈ $-3.23 Million	-3.528x	-18.07%
2015-12-31	CA$1.28 Million ≈ $929.30K	CA$-3.84 Million ≈ $-2.78 Million	-2.988x	-539.59%
2014-12-31	CA$2.92 Million ≈ $2.11 Million	CA$-1.36 Million ≈ $-987.33K	-0.467x	+85.04%
2013-12-31	CA$280.60K ≈ $202.98K	CA$-876.06K ≈ $-633.73K	-3.122x	--

About Aequus Pharmaceuticals Inc

V:AQS Canada Drug Manufacturers - Specialty & Generic

Market Cap

$479.73K

CA$663.17K CAD

Market Cap Rank

#31080 Global

#1647 in Canada

Share Price

CA$0.01

Change (1 day)

+0.00%

52-Week Range

CA$0.01 - CA$0.01

All Time High

CA$0.69